**[미래에셋 제약/바이오 김승민]**
**10/19 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [중국 정부, 특정 바이오 제약 기술 수출 금지 추진](https://endpoints.news/china-pursues-export-ban-on-some-biotech-platforms/)

 [Astrazeneca와 Insitro, AI 기반 심혈대사 질환 개발을 위한 15억 달러 규모 파트너십 체결](https://www.pharmaceutical-technology.com/news/astrazeneca-inistro-ai-cardiometabolic-drug-discovery-partnership/)

 [EMA, Lilly의 경구용 비만치료제, EU 의약품규제기관 승인 권고](https://news.google.com/rss/articles/CBMiogFBVV95cUxOUTZHdm94VW1Ya3BOUDQtTjB5UjRIOUc1RGJKM09ubjlUcWZtS3Q0RU1PbnYxT21wUEUydXh6MXdqUXphU1JXRnJaM0padHMwZUotVGJ2YVlfNUs5c0ctbGJpUUEtVXg3dl9QYVl6VllubGNzeFZQWkNINk9KWmdna3RpQlV5ekxJVkdRZ2tDUFhUYTBoQUJLNFNldXRBMkhqYWc?oc=5)

 [CHMP, J&J의 TALVEY + 다라투무맙 병용요법 다발성골수종 조기 치료 승인 권고](https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma)

 [Novartis, Fabalta 루푸스 신염 임상 2상 시험 중단](https://firstwordpharma.com/story/8227871)

 [US FDA, 의약품 독점권 결정 감시 위원회 설립](https://news.google.com/rss/articles/CBMiswFBVV95cUxQTnpzZWRTbnhGYTlYUWJscGJmYzN2ZGFXTm5iZUg2TVpUVWNZNzdtY082UW9OZEtLakdIeUlvVDJDUWZjZ3lPMGVuYmhHWllBdERldkJVYklzWUlIQUt0UzNfQVJYQ3ktYVQ1SkVmZnpRTURWMnRNN3FCZWRrSF9YTjdpSElyYnFvMzNFT2RpOFFFcnNhY0FfNW12eWdLZ0toTWptVlYzUDd0Zm1KYmtnMW1Law?oc=5)

 [인도, 암 치료제 가격 상한 인상, 137개 의약품 가격 인하](https://news.google.com/rss/articles/CBMi0wFBVV95cUxNYkkwM0RDdmdmQ1ktLWJBS05mMmp0SmNveGE5ZGRVWmNaYVA1czQwVEpSTGF0aXRSSVpYaGNYZ2tVVVVtN3Q0VUpqS1cxaVVMd3hUNkxPVEdhN2xfeHU3VjhuTkVoSlVJWDYxSXpSMkNiNUVOMGU2VUhWUTdBZUhzeUpidFhUTkhpZVFOOVRmYUV6alA3TC1BMTdYR2lJYktuZUI2UVZGMm5Wajg0MmNfMTg4NzJqeXVhVmpwNkVmbEpKbmhiUEJKUWQ4aTA3cmJTR0FR?oc=5)


 **한국 바이오/제약**
────────────────────
 [법원, 삼성바이오로직스 2차 파업 제동](https://news.google.com/rss/articles/CBMirAFBVV95cUxNMmJ5Q1h0ZndsYjBOWnJOSzktb3NtWDRiRVdtelhIR1JjcjNOckRLYW93MEtsTXJncnpCTGd3VG5MMTJMR1V3OHNYXzI4VElMUzhwQXJSTHVmWF9LaDN3NnJxSFBsTXF1WE8xa2phSXdxTTZRUzhOYUpSTUhrR056bDQxU1lvVEdrZFQ3ZUJ0X3BVTWRsR0trZ1NrYUQ4dlE0SHRNSzJQQmNPbXd1?oc=5)

 [리가켐바이오, CLDN18.2 타깃 ‘LCB02A’ 1·2상 북미서 첫 환자 투여](https://news.google.com/rss/articles/CBMibkFVX3lxTE1mazVDQ3NsbmpLZmx5OG56dWRzbzk5WmFOcEJINGN1aXcyWFBiV0JWWVNMZDllZUZMOVV5Y1ZaV0t4SHJsM3hPdHdueUZuaXdQVEVWZ1dua0JCaEpwUEM5bHVEWXJERmlhWmY5Y19n?oc=5)

 [종근당, ADC 내성 노린 'CKD-DAC' 전임상 월드ADC서 발표](https://www.hitnews.co.kr/news/articleView.html?idxno=79956)

 [앱클론, 다중 타깃 공략 CAR-T 플랫폼 기술 일본 특허 등록](https://www.hitnews.co.kr/news/articleView.html?idxno=79949)

 [한국 최초 GLP-1 신약 초고속 허가 뒤엔… 식약처 노하우·GIFT](https://www.hitnews.co.kr/news/articleView.html?idxno=79938)

 [바티젠, 글로벌제약사와 135억 위탁생산 계약](https://www.hitnews.co.kr/news/articleView.html?idxno=79946)


────────────────────